Vimentin Is a Novel Anti-Cancer Therapeutic Target; Insights from In Vitro and In Vivo Mice Xenograft Studies
Open Access
- 16 April 2010
- journal article
- retracted article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (4), e10105
- https://doi.org/10.1371/journal.pone.0010105
Abstract
Vimentin is a ubiquitous mesenchymal intermediate filament supporting mechano-structural integrity of quiescent cells while participating in adhesion, migration, survival, and cell signaling processes via dynamic assembly/disassembly in activated cells. Soft tissue sarcomas and some epithelial cancers exhibiting “epithelial to mesenchymal transition” phenotypes express vimentin. Withaferin-A, a naturally derived bioactive compound, may molecularly target vimentin, so we sought to evaluate its effects on tumor growth in vitro and in vivo thereby elucidating the role of vimentin in drug-induced responses. Withaferin-A elicited marked apoptosis and vimentin cleavage in vimentin-expressing tumor cells but significantly less in normal mesenchymal cells. This proapoptotic response was abrogated after vimentin knockdown or by blockade of caspase-induced vimentin degradation via caspase inhibitors or overexpression of mutated caspase-resistant vimentin. Pronounced anti-angiogenic effects of Withaferin-A were demonstrated, with only minimal effects seen in non-proliferating endothelial cells. Moreover, Withaferin-A significantly blocked soft tissue sarcoma growth, local recurrence, and metastasis in a panel of soft tissue sarcoma xenograft experiments. Apoptosis, decreased angiogenesis, and vimentin degradation were all seen in Withaferin-A treated specimens. In light of these findings, evaluation of Withaferin-A, its analogs, or other anti-vimentin therapeutic approaches in soft tissue sarcoma and “epithelial to mesenchymal transition” clinical contexts is warranted.Keywords
This publication has 97 references indexed in Scilit:
- Hyperactivated NF-κB and AP-1 Transcription Factors Promote Highly Accessible Chromatin and Constitutive Transcription across the Interleukin-6 Gene Promoter in Metastatic Breast Cancer CellsMolecular and Cellular Biology, 2009
- Introducing intermediate filaments: from discovery to diseaseJCI Insight, 2009
- The basics of epithelial-mesenchymal transitionJCI Insight, 2009
- Genetic aberrations in soft tissue leiomyosarcomaCancer Letters, 2009
- Withaferin A Causes FOXO3a- and Bim-Dependent Apoptosis and Inhibits Growth of Human Breast Cancer Cells In vivoCancer Research, 2008
- The Tumor Inhibitor and Antiangiogenic Agent Withaferin A Targets the Intermediate Filament Protein VimentinCell Chemical Biology, 2007
- Critical Role of Vimentin Phosphorylation at Ser-56 by p21-activated Kinase in Vimentin Cytoskeleton SignalingPublished by Elsevier BV ,2006
- A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritoneiBritish Journal of Cancer, 2006
- PKCɛ-mediated phosphorylation of vimentin controls integrin recycling and motilityThe EMBO Journal, 2005
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998